Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin.
The antibacterial activity of SCH 27899, was compared with vancomycin in vitro against 210 recent clinical isolates representing eight major genera of Gram-positive organisms. MIC90 values for everninomicin were consistently better than those of vancomycin for all Gram-positive bacteria tested. Although everninomicin was less bactericidal than vancomycin against staphylococci, it was inhibitory against vancomycin-resistant enterococci. This novel antibiotic may, therefore, provide a clinical alternative to penicillin and vancomycin for therapy of Gram-positive infections.
Urban
C
C
Department of Medicine, New York Hospital, Medical Center of Queens, Flushing 11355-5095, USA.
Mariano
N
N
Mosinka-Snipas
K
K
Wadee
C
C
Chahrour
T
T
Rahal
J J
JJ
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D014640:Vancomycin / Q000494:pharmacology*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C001202:evernimicin; D014640:Vancomycin